Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat Roll-over Study
NCT01802879Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in hematologic neoplasms, sponsored by Novartis. Primary endpoint: Overview of Adverse Events at 60 months. Started Jun 2013; status: completed.
02
Drugs
panobinostat
03
Conditions
hematologic neoplasms
Beyond the preview
Go deeper on NCT01802879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01802879.